XENETIC BIOSCIENCES, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
XENETIC BIOSCIENCES, INC. (XBIO) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of -$9.24 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2021-03-16
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2014-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2014-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2014-06-30 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was -$9.24M.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$9.24M 10-K · filed 2021-03-16 | ||
| 2020-09-30 | -$9.24M 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-30 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-31 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 derived: sum of 3 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $0.00 derived: sum of 2 quarters · filed 2014-11-14 | $0.00 10-Q · filed 2014-11-14 | $0.00 derived: sum of 4 quarters · filed 2015-07-20 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | $0.00 derived: sum of 3 quarters · filed 2015-07-20 | $0.00 derived: sum of 4 quarters · filed 2015-07-20 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-20 | $0.00 derived: sum of 2 quarters · filed 2015-07-20 | $0.00 derived: sum of 3 quarters · filed 2015-07-20 | $0.00 derived: sum of 4 quarters · filed 2015-07-20 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-20 | $0.00 derived: sum of 2 quarters · filed 2015-07-20 | $0.00 derived: sum of 3 quarters · filed 2015-07-20 | $0.00 10-K · filed 2015-07-20 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $0.00 derived: sum of 2 quarters · filed 2014-11-14 | $0.00 10-Q · filed 2014-11-14 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-20 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |